The decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?
Dean Erhardt
Advertisement
Articles by Dean Erhardt
![Dean Erhardt[1].jpg](https://cdn.sanity.io/images/0vv8moc6/pharmexec/eb3013cb10f0ac51d7ac205d81f227635a714120-3000x3900.jpg?w=350&fit=crop&auto=format)
A rule to eradicate drug rebates and prompt direct discounts for federal beneficiaries raises challenging questions for drug manufacturers and other stakeholders.
Advertisement
Latest Updated Articles
![Dean Erhardt[1].jpg](https://cdn.sanity.io/images/0vv8moc6/pharmexec/eb3013cb10f0ac51d7ac205d81f227635a714120-3000x3900.jpg?w=300&fit=crop&auto=format)
Proposed Rule to Eliminate Pharmaceutical Rebates Raises Challenging QuestionsPublished: May 22nd 2019 | Updated:
Proposed Rebates Rule Raises Tough QuestionsPublished: July 16th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
FDA Announces Agency-Wide Deployment of Agentic AI Tools
4
Report: FDA to Change Vaccine Approval Process Based on Agency’s Claim of Covid Vaccine-Related Deaths
5
